Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Prise en charge du trouble de consommation d’opioïdes en première ligne: Lignes directrices simplifiées de PEER.

Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, Lamba W, Marlinga J, Mogus T, Nickonchuk T, Orrantia E, Reich K, Wong N, Dugré N, Lindblad AJ.

Can Fam Physician. 2019 May;65(5):e173-e184. French.

PMID:
31088882
Free Article
2.

Managing opioid use disorder in primary care: PEER simplified guideline.

Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, Lamba W, Marlinga J, Mogus T, Nickonchuk T, Orrantia E, Reich K, Wong N, Dugré N, Lindblad AJ.

Can Fam Physician. 2019 May;65(5):321-330.

3.

The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes.

Goel A, Azargive S, Lamba W, Bordman J, Englesakis M, Srikandarajah S, Ladha K, Di Renna T, Shanthanna H, Duggan S, Peng P, Hanlon J, Clarke H.

Can J Anaesth. 2019 Feb;66(2):201-217. doi: 10.1007/s12630-018-1255-3. Epub 2018 Nov 27.

PMID:
30484167
4.

Endocarditis in the setting of IDU: multidisciplinary management.

Yanagawa B, Bahji A, Lamba W, Tan DH, Cheema A, Syed I, Verma S.

Curr Opin Cardiol. 2018 Mar;33(2):140-147. doi: 10.1097/HCO.0000000000000493.

PMID:
29232248
5.

Harm reduction in hospitals.

Sharma M, Lamba W, Cauderella A, Guimond TH, Bayoumi AM.

Harm Reduct J. 2017 Jun 5;14(1):32. doi: 10.1186/s12954-017-0163-0. No abstract available.

6.

Alcohol use disorder and depression: proposed rewording of Choosing Wisely recommendation.

Tanguay RL, Lamba W, Fraser R, Mills P, Azarbar A, El-Guebaly N.

CMAJ. 2017 Mar 20;189(11):E442-E443. doi: 10.1503/cmaj.732873. No abstract available.

7.

Characterization of lymphoproliferative lesions of the conjunctiva: immunohistochemical and molecular genetic studies.

Farmer JP, Lamba M, Merkur AB, Lamba WR, Hodge WG, Jordan DR, Sengar DP, Burns BF.

Can J Ophthalmol. 2006 Dec;41(6):753-60.

PMID:
17224959
8.

Regulation of axotomy-induced dopaminergic neuron death and c-Jun phosphorylation by targeted inhibition of cdc42 or mixed lineage kinase.

Crocker SJ, Hayley SP, Smith PD, Mount MP, Lamba WR, Callaghan SM, Slack RS, Park DS.

J Neurochem. 2006 Jan;96(2):489-99. Epub 2005 Nov 29.

9.

MPTP induces intranuclear rodlet formation in midbrain dopaminergic neurons.

Lamba W, Prichett W, Munoz D, Park DS, Woulfe JM.

Brain Res. 2005 Dec 20;1066(1-2):86-91. Epub 2005 Dec 1.

PMID:
16325158
10.

Lymphoproliferative lesions of the lacrimal gland: clinicopathological, immunohistochemical and molecular genetic analysis.

Farmer JP, Lamba M, Lamba WR, Jordan DR, Gilberg S, Sengar DP, Bence-Bruckler I, Burns BF.

Can J Ophthalmol. 2005 Apr;40(2):151-60.

PMID:
16049528
11.

Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease.

Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborski S, Robertson GS, Anisman H, Merali Z, Park DS.

J Neurosci. 2003 May 15;23(10):4081-91.

12.

c-Jun mediates axotomy-induced dopamine neuron death in vivo.

Crocker SJ, Lamba WR, Smith PD, Callaghan SM, Slack RS, Anisman H, Park DS.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13385-90. Epub 2001 Oct 30.

Supplemental Content

Support Center